Systemic Lupus Erythematosus Activity Affects the Sinusoidal Uptake Transporter OATP1B1 Evaluated by the Pharmacokinetics of Atorvastatin

The present study assessed the effect of systemic lupus erythematosus (SLE) activity, a chronic and inflammatory autoimmune disease, on the sinusoidal uptake transporter OATP1B1 using atorvastatin (ATV) as a probe drug. Fifteen healthy subjects, 13 patients with controlled SLE (SLEDAI 0–4), and 12 p...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Clinical and translational science 2020-11, Vol.13 (6), p.1227-1235
Hauptverfasser: Cestari, Roberta Natália, Oliveira, Renê Donizeti Ribeiro, Souza, Flávio Falcão Lima, Pippa, Leandro Francisco, Nardotto, Glauco Henrique Balthazar, Rocha, Adriana, Donadi, Eduardo Antônio, Lanchote, Vera Lucia
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 1235
container_issue 6
container_start_page 1227
container_title Clinical and translational science
container_volume 13
creator Cestari, Roberta Natália
Oliveira, Renê Donizeti Ribeiro
Souza, Flávio Falcão Lima
Pippa, Leandro Francisco
Nardotto, Glauco Henrique Balthazar
Rocha, Adriana
Donadi, Eduardo Antônio
Lanchote, Vera Lucia
description The present study assessed the effect of systemic lupus erythematosus (SLE) activity, a chronic and inflammatory autoimmune disease, on the sinusoidal uptake transporter OATP1B1 using atorvastatin (ATV) as a probe drug. Fifteen healthy subjects, 13 patients with controlled SLE (SLEDAI 0–4), and 12 patients with uncontrolled SLE (SLEDAI from 6 to 15), all women, were investigated. Apparent total clearance of midazolam (MDZ), a marker of CYP3A4 activity, did not vary among the three investigated groups. The controlled and uncontrolled SLE groups showed higher plasma concentrations of MCP‐1 and TNF‐α, while the uncontrolled SLE group also showed higher plasma concentrations of IL‐10. The uncontrolled SLE group showed higher area under the curve (AUC) for ATV (60.47 (43.76–83.56) vs. 30.56 (22.69–41.15) ng⋅hour/mL) and its inactive metabolite ATV‐lactone (98.74 (74.31–131.20) vs. 49.21 (34.89–69.42) ng⋅hour/mL), and lower apparent total clearance (330.7 (239.30–457.00) vs. 654.5 (486.00–881.4) L/hour) and apparent volume of distribution (2,609 (1,607–4,234) vs. 7,159 (4,904–10,450) L), when compared to the healthy subjects group (geometric mean and 95% confidence interval). The pharmacokinetics of ATV and its metabolites did not differ between the healthy subject group and the patients with controlled SLE group. In conclusion, uncontrolled SLE increased the systemic exposure to both ATV and ATV‐lactone, inferring inhibition of OATP1B1 activity, once in vivo CYP3A4 activity assessed by oral clearance of MDZ was unaltered. The inflammatory state, not the disease itself, was responsible for the changes described in the uncontrolled SLE group as a consequence of inhibition of OATP1B1, because systemic exposure to ATV and its metabolites were not altered in patients with controlled SLE.
doi_str_mv 10.1111/cts.12808
format Article
fullrecord <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_7719393</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2467445368</sourcerecordid><originalsourceid>FETCH-LOGICAL-c4438-617f01577a54edbf03edcf4570e6cd3e6ee996639db8955fa1163a1f6b2ba4dd3</originalsourceid><addsrcrecordid>eNp1kc1u1DAUhSMEoqVlwQsgS6xYTGvHP0k2SOlogEojtdJM19aNYzNukzjYzqA8Am-N6ZRRWdQb27rfPffqnCz7QPAFSedSxXBB8hKXr7JTUvB8UWKRvz6-OTvJ3oVwj7GgouRvsxOaM0G5EKfZ780cou6tQutpnAJa-TnudA_RhfSrVbR7G2dUG6PTFJRqaGOHKTjbQofuxggPGm09DGF0PmqPburtLbkiaLWHboKoW9TMj223O_A9KPdgBx2tCsgZVEfn9xAiRDucZ28MdEG_f7rPsruvq-3y-2J98-16Wa8XijFaLgQpDCa8KIAz3TYGU90qw3iBtVAt1ULrqhKCVm1TVpwbIERQIEY0eQOsbelZ9uWgO05Nn3r1ED10cvS2Bz9LB1b-XxnsTv5we1kUpKIVTQKfngS8-znpEOW9m_yQdpbJ1oIxnlxO1OcDpbwLwWtznECw_JuaTH7Kx9QS-_H5SkfyX0wJuDwAv2yn55eV5HK7OUj-ATM9pWk</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2467445368</pqid></control><display><type>article</type><title>Systemic Lupus Erythematosus Activity Affects the Sinusoidal Uptake Transporter OATP1B1 Evaluated by the Pharmacokinetics of Atorvastatin</title><source>Wiley Journals</source><source>DOAJ Directory of Open Access Journals</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>Wiley Online Library (Open Access Collection)</source><source>PubMed Central</source><creator>Cestari, Roberta Natália ; Oliveira, Renê Donizeti Ribeiro ; Souza, Flávio Falcão Lima ; Pippa, Leandro Francisco ; Nardotto, Glauco Henrique Balthazar ; Rocha, Adriana ; Donadi, Eduardo Antônio ; Lanchote, Vera Lucia</creator><creatorcontrib>Cestari, Roberta Natália ; Oliveira, Renê Donizeti Ribeiro ; Souza, Flávio Falcão Lima ; Pippa, Leandro Francisco ; Nardotto, Glauco Henrique Balthazar ; Rocha, Adriana ; Donadi, Eduardo Antônio ; Lanchote, Vera Lucia</creatorcontrib><description>The present study assessed the effect of systemic lupus erythematosus (SLE) activity, a chronic and inflammatory autoimmune disease, on the sinusoidal uptake transporter OATP1B1 using atorvastatin (ATV) as a probe drug. Fifteen healthy subjects, 13 patients with controlled SLE (SLEDAI 0–4), and 12 patients with uncontrolled SLE (SLEDAI from 6 to 15), all women, were investigated. Apparent total clearance of midazolam (MDZ), a marker of CYP3A4 activity, did not vary among the three investigated groups. The controlled and uncontrolled SLE groups showed higher plasma concentrations of MCP‐1 and TNF‐α, while the uncontrolled SLE group also showed higher plasma concentrations of IL‐10. The uncontrolled SLE group showed higher area under the curve (AUC) for ATV (60.47 (43.76–83.56) vs. 30.56 (22.69–41.15) ng⋅hour/mL) and its inactive metabolite ATV‐lactone (98.74 (74.31–131.20) vs. 49.21 (34.89–69.42) ng⋅hour/mL), and lower apparent total clearance (330.7 (239.30–457.00) vs. 654.5 (486.00–881.4) L/hour) and apparent volume of distribution (2,609 (1,607–4,234) vs. 7,159 (4,904–10,450) L), when compared to the healthy subjects group (geometric mean and 95% confidence interval). The pharmacokinetics of ATV and its metabolites did not differ between the healthy subject group and the patients with controlled SLE group. In conclusion, uncontrolled SLE increased the systemic exposure to both ATV and ATV‐lactone, inferring inhibition of OATP1B1 activity, once in vivo CYP3A4 activity assessed by oral clearance of MDZ was unaltered. The inflammatory state, not the disease itself, was responsible for the changes described in the uncontrolled SLE group as a consequence of inhibition of OATP1B1, because systemic exposure to ATV and its metabolites were not altered in patients with controlled SLE.</description><identifier>ISSN: 1752-8054</identifier><identifier>EISSN: 1752-8062</identifier><identifier>DOI: 10.1111/cts.12808</identifier><identifier>PMID: 32463566</identifier><language>eng</language><publisher>United States: John Wiley &amp; Sons, Inc</publisher><subject>Acids ; Age ; Atorvastatin ; Autoimmune diseases ; Body mass index ; Cytokines ; Disease ; Drug dosages ; Enzymes ; Inflammation ; Laboratories ; Lipoproteins ; Liver ; Lupus ; Metabolism ; Metabolites ; Midazolam ; Pharmacokinetics ; Plasma ; Proteins ; Systemic lupus erythematosus ; Tumor necrosis factor ; Tumor necrosis factor-TNF</subject><ispartof>Clinical and translational science, 2020-11, Vol.13 (6), p.1227-1235</ispartof><rights>2020 The Authors. Clinical and Translational Science published by Wiley Periodicals LLC on behalf of American Society for Clinical Pharmacology and Therapeutics.</rights><rights>2020. This work is published under http://creativecommons.org/licenses/by-nc-nd/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c4438-617f01577a54edbf03edcf4570e6cd3e6ee996639db8955fa1163a1f6b2ba4dd3</citedby><cites>FETCH-LOGICAL-c4438-617f01577a54edbf03edcf4570e6cd3e6ee996639db8955fa1163a1f6b2ba4dd3</cites><orcidid>0000-0002-2782-0389 ; 0000-0003-1004-8916 ; 0000-0002-0074-4953 ; 0000-0001-7024-4252</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC7719393/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC7719393/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,727,780,784,864,885,1417,11562,27924,27925,45574,45575,46052,46476,53791,53793</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/32463566$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Cestari, Roberta Natália</creatorcontrib><creatorcontrib>Oliveira, Renê Donizeti Ribeiro</creatorcontrib><creatorcontrib>Souza, Flávio Falcão Lima</creatorcontrib><creatorcontrib>Pippa, Leandro Francisco</creatorcontrib><creatorcontrib>Nardotto, Glauco Henrique Balthazar</creatorcontrib><creatorcontrib>Rocha, Adriana</creatorcontrib><creatorcontrib>Donadi, Eduardo Antônio</creatorcontrib><creatorcontrib>Lanchote, Vera Lucia</creatorcontrib><title>Systemic Lupus Erythematosus Activity Affects the Sinusoidal Uptake Transporter OATP1B1 Evaluated by the Pharmacokinetics of Atorvastatin</title><title>Clinical and translational science</title><addtitle>Clin Transl Sci</addtitle><description>The present study assessed the effect of systemic lupus erythematosus (SLE) activity, a chronic and inflammatory autoimmune disease, on the sinusoidal uptake transporter OATP1B1 using atorvastatin (ATV) as a probe drug. Fifteen healthy subjects, 13 patients with controlled SLE (SLEDAI 0–4), and 12 patients with uncontrolled SLE (SLEDAI from 6 to 15), all women, were investigated. Apparent total clearance of midazolam (MDZ), a marker of CYP3A4 activity, did not vary among the three investigated groups. The controlled and uncontrolled SLE groups showed higher plasma concentrations of MCP‐1 and TNF‐α, while the uncontrolled SLE group also showed higher plasma concentrations of IL‐10. The uncontrolled SLE group showed higher area under the curve (AUC) for ATV (60.47 (43.76–83.56) vs. 30.56 (22.69–41.15) ng⋅hour/mL) and its inactive metabolite ATV‐lactone (98.74 (74.31–131.20) vs. 49.21 (34.89–69.42) ng⋅hour/mL), and lower apparent total clearance (330.7 (239.30–457.00) vs. 654.5 (486.00–881.4) L/hour) and apparent volume of distribution (2,609 (1,607–4,234) vs. 7,159 (4,904–10,450) L), when compared to the healthy subjects group (geometric mean and 95% confidence interval). The pharmacokinetics of ATV and its metabolites did not differ between the healthy subject group and the patients with controlled SLE group. In conclusion, uncontrolled SLE increased the systemic exposure to both ATV and ATV‐lactone, inferring inhibition of OATP1B1 activity, once in vivo CYP3A4 activity assessed by oral clearance of MDZ was unaltered. The inflammatory state, not the disease itself, was responsible for the changes described in the uncontrolled SLE group as a consequence of inhibition of OATP1B1, because systemic exposure to ATV and its metabolites were not altered in patients with controlled SLE.</description><subject>Acids</subject><subject>Age</subject><subject>Atorvastatin</subject><subject>Autoimmune diseases</subject><subject>Body mass index</subject><subject>Cytokines</subject><subject>Disease</subject><subject>Drug dosages</subject><subject>Enzymes</subject><subject>Inflammation</subject><subject>Laboratories</subject><subject>Lipoproteins</subject><subject>Liver</subject><subject>Lupus</subject><subject>Metabolism</subject><subject>Metabolites</subject><subject>Midazolam</subject><subject>Pharmacokinetics</subject><subject>Plasma</subject><subject>Proteins</subject><subject>Systemic lupus erythematosus</subject><subject>Tumor necrosis factor</subject><subject>Tumor necrosis factor-TNF</subject><issn>1752-8054</issn><issn>1752-8062</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2020</creationdate><recordtype>article</recordtype><sourceid>24P</sourceid><sourceid>WIN</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><sourceid>GNUQQ</sourceid><recordid>eNp1kc1u1DAUhSMEoqVlwQsgS6xYTGvHP0k2SOlogEojtdJM19aNYzNukzjYzqA8Am-N6ZRRWdQb27rfPffqnCz7QPAFSedSxXBB8hKXr7JTUvB8UWKRvz6-OTvJ3oVwj7GgouRvsxOaM0G5EKfZ780cou6tQutpnAJa-TnudA_RhfSrVbR7G2dUG6PTFJRqaGOHKTjbQofuxggPGm09DGF0PmqPburtLbkiaLWHboKoW9TMj223O_A9KPdgBx2tCsgZVEfn9xAiRDucZ28MdEG_f7rPsruvq-3y-2J98-16Wa8XijFaLgQpDCa8KIAz3TYGU90qw3iBtVAt1ULrqhKCVm1TVpwbIERQIEY0eQOsbelZ9uWgO05Nn3r1ED10cvS2Bz9LB1b-XxnsTv5we1kUpKIVTQKfngS8-znpEOW9m_yQdpbJ1oIxnlxO1OcDpbwLwWtznECw_JuaTH7Kx9QS-_H5SkfyX0wJuDwAv2yn55eV5HK7OUj-ATM9pWk</recordid><startdate>202011</startdate><enddate>202011</enddate><creator>Cestari, Roberta Natália</creator><creator>Oliveira, Renê Donizeti Ribeiro</creator><creator>Souza, Flávio Falcão Lima</creator><creator>Pippa, Leandro Francisco</creator><creator>Nardotto, Glauco Henrique Balthazar</creator><creator>Rocha, Adriana</creator><creator>Donadi, Eduardo Antônio</creator><creator>Lanchote, Vera Lucia</creator><general>John Wiley &amp; Sons, Inc</general><general>John Wiley and Sons Inc</general><scope>24P</scope><scope>WIN</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7QP</scope><scope>7T5</scope><scope>7TK</scope><scope>7TM</scope><scope>7U9</scope><scope>7X7</scope><scope>7XB</scope><scope>8FD</scope><scope>8FE</scope><scope>8FH</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FR3</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>H94</scope><scope>HCIFZ</scope><scope>K9.</scope><scope>LK8</scope><scope>M0S</scope><scope>M7N</scope><scope>M7P</scope><scope>P64</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>RC3</scope><scope>5PM</scope><orcidid>https://orcid.org/0000-0002-2782-0389</orcidid><orcidid>https://orcid.org/0000-0003-1004-8916</orcidid><orcidid>https://orcid.org/0000-0002-0074-4953</orcidid><orcidid>https://orcid.org/0000-0001-7024-4252</orcidid></search><sort><creationdate>202011</creationdate><title>Systemic Lupus Erythematosus Activity Affects the Sinusoidal Uptake Transporter OATP1B1 Evaluated by the Pharmacokinetics of Atorvastatin</title><author>Cestari, Roberta Natália ; Oliveira, Renê Donizeti Ribeiro ; Souza, Flávio Falcão Lima ; Pippa, Leandro Francisco ; Nardotto, Glauco Henrique Balthazar ; Rocha, Adriana ; Donadi, Eduardo Antônio ; Lanchote, Vera Lucia</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c4438-617f01577a54edbf03edcf4570e6cd3e6ee996639db8955fa1163a1f6b2ba4dd3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2020</creationdate><topic>Acids</topic><topic>Age</topic><topic>Atorvastatin</topic><topic>Autoimmune diseases</topic><topic>Body mass index</topic><topic>Cytokines</topic><topic>Disease</topic><topic>Drug dosages</topic><topic>Enzymes</topic><topic>Inflammation</topic><topic>Laboratories</topic><topic>Lipoproteins</topic><topic>Liver</topic><topic>Lupus</topic><topic>Metabolism</topic><topic>Metabolites</topic><topic>Midazolam</topic><topic>Pharmacokinetics</topic><topic>Plasma</topic><topic>Proteins</topic><topic>Systemic lupus erythematosus</topic><topic>Tumor necrosis factor</topic><topic>Tumor necrosis factor-TNF</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Cestari, Roberta Natália</creatorcontrib><creatorcontrib>Oliveira, Renê Donizeti Ribeiro</creatorcontrib><creatorcontrib>Souza, Flávio Falcão Lima</creatorcontrib><creatorcontrib>Pippa, Leandro Francisco</creatorcontrib><creatorcontrib>Nardotto, Glauco Henrique Balthazar</creatorcontrib><creatorcontrib>Rocha, Adriana</creatorcontrib><creatorcontrib>Donadi, Eduardo Antônio</creatorcontrib><creatorcontrib>Lanchote, Vera Lucia</creatorcontrib><collection>Wiley Online Library (Open Access Collection)</collection><collection>Wiley Online Library (Open Access Collection)</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Calcium &amp; Calcified Tissue Abstracts</collection><collection>Immunology Abstracts</collection><collection>Neurosciences Abstracts</collection><collection>Nucleic Acids Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>Health &amp; Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Technology Research Database</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>ProQuest Central</collection><collection>Natural Science Collection</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Engineering Research Database</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>SciTech Premium Collection</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>ProQuest Biological Science Collection</collection><collection>Health &amp; Medical Collection (Alumni Edition)</collection><collection>Algology Mycology and Protozoology Abstracts (Microbiology C)</collection><collection>Biological Science Database</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>Access via ProQuest (Open Access)</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>Genetics Abstracts</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Clinical and translational science</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Cestari, Roberta Natália</au><au>Oliveira, Renê Donizeti Ribeiro</au><au>Souza, Flávio Falcão Lima</au><au>Pippa, Leandro Francisco</au><au>Nardotto, Glauco Henrique Balthazar</au><au>Rocha, Adriana</au><au>Donadi, Eduardo Antônio</au><au>Lanchote, Vera Lucia</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Systemic Lupus Erythematosus Activity Affects the Sinusoidal Uptake Transporter OATP1B1 Evaluated by the Pharmacokinetics of Atorvastatin</atitle><jtitle>Clinical and translational science</jtitle><addtitle>Clin Transl Sci</addtitle><date>2020-11</date><risdate>2020</risdate><volume>13</volume><issue>6</issue><spage>1227</spage><epage>1235</epage><pages>1227-1235</pages><issn>1752-8054</issn><eissn>1752-8062</eissn><abstract>The present study assessed the effect of systemic lupus erythematosus (SLE) activity, a chronic and inflammatory autoimmune disease, on the sinusoidal uptake transporter OATP1B1 using atorvastatin (ATV) as a probe drug. Fifteen healthy subjects, 13 patients with controlled SLE (SLEDAI 0–4), and 12 patients with uncontrolled SLE (SLEDAI from 6 to 15), all women, were investigated. Apparent total clearance of midazolam (MDZ), a marker of CYP3A4 activity, did not vary among the three investigated groups. The controlled and uncontrolled SLE groups showed higher plasma concentrations of MCP‐1 and TNF‐α, while the uncontrolled SLE group also showed higher plasma concentrations of IL‐10. The uncontrolled SLE group showed higher area under the curve (AUC) for ATV (60.47 (43.76–83.56) vs. 30.56 (22.69–41.15) ng⋅hour/mL) and its inactive metabolite ATV‐lactone (98.74 (74.31–131.20) vs. 49.21 (34.89–69.42) ng⋅hour/mL), and lower apparent total clearance (330.7 (239.30–457.00) vs. 654.5 (486.00–881.4) L/hour) and apparent volume of distribution (2,609 (1,607–4,234) vs. 7,159 (4,904–10,450) L), when compared to the healthy subjects group (geometric mean and 95% confidence interval). The pharmacokinetics of ATV and its metabolites did not differ between the healthy subject group and the patients with controlled SLE group. In conclusion, uncontrolled SLE increased the systemic exposure to both ATV and ATV‐lactone, inferring inhibition of OATP1B1 activity, once in vivo CYP3A4 activity assessed by oral clearance of MDZ was unaltered. The inflammatory state, not the disease itself, was responsible for the changes described in the uncontrolled SLE group as a consequence of inhibition of OATP1B1, because systemic exposure to ATV and its metabolites were not altered in patients with controlled SLE.</abstract><cop>United States</cop><pub>John Wiley &amp; Sons, Inc</pub><pmid>32463566</pmid><doi>10.1111/cts.12808</doi><tpages>9</tpages><orcidid>https://orcid.org/0000-0002-2782-0389</orcidid><orcidid>https://orcid.org/0000-0003-1004-8916</orcidid><orcidid>https://orcid.org/0000-0002-0074-4953</orcidid><orcidid>https://orcid.org/0000-0001-7024-4252</orcidid><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 1752-8054
ispartof Clinical and translational science, 2020-11, Vol.13 (6), p.1227-1235
issn 1752-8054
1752-8062
language eng
recordid cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_7719393
source Wiley Journals; DOAJ Directory of Open Access Journals; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; Wiley Online Library (Open Access Collection); PubMed Central
subjects Acids
Age
Atorvastatin
Autoimmune diseases
Body mass index
Cytokines
Disease
Drug dosages
Enzymes
Inflammation
Laboratories
Lipoproteins
Liver
Lupus
Metabolism
Metabolites
Midazolam
Pharmacokinetics
Plasma
Proteins
Systemic lupus erythematosus
Tumor necrosis factor
Tumor necrosis factor-TNF
title Systemic Lupus Erythematosus Activity Affects the Sinusoidal Uptake Transporter OATP1B1 Evaluated by the Pharmacokinetics of Atorvastatin
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-23T13%3A14%3A11IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Systemic%20Lupus%20Erythematosus%20Activity%20Affects%20the%20Sinusoidal%20Uptake%20Transporter%20OATP1B1%20Evaluated%20by%20the%20Pharmacokinetics%20of%20Atorvastatin&rft.jtitle=Clinical%20and%20translational%20science&rft.au=Cestari,%20Roberta%20Nat%C3%A1lia&rft.date=2020-11&rft.volume=13&rft.issue=6&rft.spage=1227&rft.epage=1235&rft.pages=1227-1235&rft.issn=1752-8054&rft.eissn=1752-8062&rft_id=info:doi/10.1111/cts.12808&rft_dat=%3Cproquest_pubme%3E2467445368%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2467445368&rft_id=info:pmid/32463566&rfr_iscdi=true